xxxxx xxxx
xxxxxxxx xxxxxxxx
xxx xx xxxxxxxx xxx
xxxx xxxxxxxxxx
xxxxxxxx xxxxxxxx
Subscribe to read this content
Subscribe nowExecutive Summary
Created by an expert team of ophthalmologists and video game specialists (Tilak Healthcare), OdySight is a mobile medical game, used for close monitoring of patients with maculopathies. Prescribed as a medical device, the application offers digitized visual tests directly adapted from those performed in the medical office, as well as a puzzle game, stimulating cognitive and visual abilities. The application contributes to a better follow-up of the patient between treatments, allowing among other things, an early detection of the evolution of the disease.
Scorecard
Subscribe to read this content
Subscribe nowWhite Paper
Context and Need
Age-related macular degeneration (AMD) is a chronic, degenerative disease affecting the central area of the retina, resulting in a progressive loss of central vision.
Read more...Digital Solution
Tilak Healthcare is positioning itself to bring the concept of "play" into the monitoring of people with chronic eye diseases, with a tool that will have established medical reliability, similar to that of tests performed in doctors' offices, and that will make it possible to monitor patients who need it most. "You Play, We Care" represents their slogan and their mission as a company.
Read more...Business Development
In order to promote OdySight, Tilak Healthcare has signed an exclusive co-promotion partnership with Novartis France in 2019. Tilak Healthcare relies on hospital and medical representatives from Novartis France to inform physicians about this innovation and allow greater access to this solution.
Read more...Use Case at a Glance
Dr Quaranta has started prescribing OdySight in February 2020 (5 months of use at the time of our interview). She found the idea interesting. In her consultations, she has always insisted on self-monitoring without being sure that patients were doing it properly. She attended demonstrations by Tilak at the beginning of the project, then attended meetings with Novartis who presented the project. Thanks to these demonstrations and the discovery of the product, the doctor was able to conclude to that the system seems very sensitive and very effective.
Read more...